Effect of rosiglitazone, metformin and medical nutrition treatment on arterial stiffness, serum MMP-9 and MCP-1 levels in drug naive type 2 diabetic patients

Simple item page
dc.contributor.authorDuran, Cevdet
dc.contributor.buuauthorKıyıcı, Sinem
dc.contributor.buuauthorErsoy, Canan
dc.contributor.buuauthorKaderli, Aysel Aydın
dc.contributor.buuauthorFazlıoğlu, Murat
dc.contributor.buuauthorBudak, Ferah
dc.contributor.buuauthorGül, Özen Öz
dc.contributor.buuauthorSığırlı, Deniz
dc.contributor.buuauthorBaran, İbrahim
dc.contributor.buuauthorTuncel, Ercan
dc.contributor.buuauthorErtürk, Erdinç
dc.contributor.buuauthorİmamoğlu, Sazi
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Endokrinoloji ve Metabolizma Anabilim Dalı.tr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Kardiyoloji Anabilim Dalı.tr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/İmmünoloji Anabilim Dalı.tr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Biyoistatistik Anabilim Dalı.tr_TR
dc.contributor.researcheridAAJ-6536-2021tr_TR
dc.contributor.researcheridAAA-7472-2021tr_TR
dc.contributor.researcheridF-4657-2014tr_TR
dc.contributor.researcheridAAI-1005-2021tr_TR
dc.contributor.scopusid12753880400tr_TR
dc.contributor.scopusid6701485882tr_TR
dc.contributor.scopusid7801322152tr_TR
dc.contributor.scopusid23988764000tr_TR
dc.contributor.scopusid6701913697tr_TR
dc.contributor.scopusid26040787100tr_TR
dc.contributor.scopusid24482063400tr_TR
dc.contributor.scopusid35572557400tr_TR
dc.contributor.scopusid7006929833tr_TR
dc.contributor.scopusid7005488796tr_TR
dc.contributor.scopusid6602297533tr_TR
dc.date.accessioned2022-04-27T06:41:10Z
dc.date.available2022-04-27T06:41:10Z
dc.date.issued2009-10
dc.description.abstractThe aim of the study was to evaluate the long-term effect of rosiglitazone and metformin monotherapy with medical nutrition treatment (MNT) and of MNT alone on arterial stiffness, serum monocyte chemoattractant protein (MCP)-1 and matrix metalloproteinase (MMP)-9 in drug naive patients with type 2 diabetes mellitus. Fifty type 2 diabetic patients were randomized to receive rosiglitazone 4 mg/day (n = 19) or metformin 850 mg/day (n = 16) with MNT or MNT alone (n = 15), for 52 weeks. Arterial stiffness was assessed by using large and small artery elasticity index (SAEI and LAEI, respectively). SAEI, LAEI, serum MCP-1 and MMP-9 levels were measured at baseline and following 52 weeks of treatment. SAEI was improved only in the rosiglitazone group, and the difference was still statistically significant when the three groups were compared (p = 0.024). There were no differences in LAEI in inter- and intragroup comparisons at the end of the study. Serum MMP-9 levels were decreased in the metformin (-13.5 +/- 34.8%, p = 0.02) and rosiglitazone (-27.2 +/- 51.0%, p = 0.023) groups compared with baseline values, whereas no significant change was seen in serum MCP-1 levels. These results suggest that rosightazone monotherapy has favorable effects on arterial stiffness compared with metformin monotherapy independent of glycemic control.en_US
dc.identifier.citationKıyıcı, S. vd. (2009). "Effect of rosiglitazone, metformin and medical nutrition treatment on arterial stiffness, serum MMP-9 and MCP-1 levels in drug naive type 2 diabetic patients". Diabetes Research and Clinical Practice, 86(1), 44-50.en_US
dc.identifier.endpage50tr_TR
dc.identifier.issn0168-8227
dc.identifier.issue1tr_TR
dc.identifier.pubmed19674806tr_TR
dc.identifier.scopus2-s2.0-69849104827tr_TR
dc.identifier.startpage44tr_TR
dc.identifier.urihttps://doi.org/10.1016/j.diabres.2009.07.004
dc.identifier.urihttps://www.sciencedirect.com/science/article/pii/S0168822709003040
dc.identifier.urihttp://hdl.handle.net/11452/26144
dc.identifier.volume86tr_TR
dc.identifier.wos000270769700007tr_TR
dc.indexed.pubmedPubMeden_US
dc.indexed.scopusScopusen_US
dc.indexed.wosSCIEen_US
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.relation.collaborationSanayitr_TR
dc.relation.journalDiabetes Research and Clinical Practiceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectArterial stiffnessen_US
dc.subjectMCP-1en_US
dc.subjectMetforminen_US
dc.subjectMMP-9en_US
dc.subjectRosiglitazoneen_US
dc.subjectMonocyte chemoattractant protein-1en_US
dc.subjectEndothelial functionen_US
dc.subjectMatrix metalloproteinasesen_US
dc.subjectCardiovascular-diseaseen_US
dc.subjectMetabolic parametersen_US
dc.subjectInsulin sensitivityen_US
dc.subjectGlucose-toleranceen_US
dc.subjectTerm treatmenten_US
dc.subjectMarkersen_US
dc.subjectElasticityen_US
dc.subjectEndocrinology & metabolismen_US
dc.subject.emtreeDipeptidyl carboxypeptidase inhibitoren_US
dc.subject.emtreeGelatinase Ben_US
dc.subject.emtreeMetforminen_US
dc.subject.emtreeMonocyte chemotactic protein 1en_US
dc.subject.emtreeRosiglitazoneen_US
dc.subject.emtreeAdulten_US
dc.subject.emtreeAgeden_US
dc.subject.emtreeArterial stiffnessen_US
dc.subject.emtreeArticleen_US
dc.subject.emtreeClinical articleen_US
dc.subject.emtreeClinical trialen_US
dc.subject.emtreeComorbidityen_US
dc.subject.emtreeControlled clinical trialen_US
dc.subject.emtreeControlled studyen_US
dc.subject.emtreeDiet therapyen_US
dc.subject.emtreeDietary intakeen_US
dc.subject.emtreeDrug efficacyen_US
dc.subject.emtreeDrug exposureen_US
dc.subject.emtreeDrug mechanisen_US
dc.subject.emtreeDrug responseen_US
dc.subject.emtreeElasticityen_US
dc.subject.emtreeFemaleen_US
dc.subject.emtreeFollow upen_US
dc.subject.emtreeGlycemic controlen_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeHypertensionen_US
dc.subject.emtreeLifestyle modificationen_US
dc.subject.emtreeLong term careen_US
dc.subject.emtreeMaleen_US
dc.subject.emtreeNon insulin dependent diabetes mellitusen_US
dc.subject.emtreeOpen studyen_US
dc.subject.emtreeProtein blood levelen_US
dc.subject.emtreeRandomized controlled trialen_US
dc.subject.meshChemokine CCL2en_US
dc.subject.meshDiabetes mellitus, type 2en_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshHypoglycemic agentsen_US
dc.subject.meshMaleen_US
dc.subject.meshMatrix metalloproteinase 9en_US
dc.subject.meshMetforminen_US
dc.subject.meshMiddle ageden_US
dc.subject.meshThiazolidinedionesen_US
dc.subject.meshVascular resistanceen_US
dc.subject.scopusGlitazone Derivative; Pioglitazone; Non Insulin Dependent Diabetes Mellitusen_US
dc.subject.wosEndocrinology & metabolismen_US
dc.titleEffect of rosiglitazone, metformin and medical nutrition treatment on arterial stiffness, serum MMP-9 and MCP-1 levels in drug naive type 2 diabetic patientsen_US
dc.typeArticle
dc.wos.quartileQ3en_US

Files

License bundle
Now showing 1 - 1 of 1
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Web of Science
Scopus